Literature DB >> 17202425

Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.

Alexander F Hoffman1, Murat Oz, Ruiqin Yang, Aron H Lichtman, Carl R Lupica.   

Abstract

Memory deficits produced by marijuana arise partly via interaction of the psychoactive component, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), with cannabinoid receptors in the hippocampus. Although cannabinoids acutely reduce glutamate release and block hippocampal long-term potentiation (LTP), a potential substrate for learning and memory, the consequences of prolonged exposure to Delta(9)-THC for hippocampal function are poorly understood. Rats were injected with Delta(9)-THC (10 mg/kg, i.p., q.d.) for 1, 3, or 7 d, and electrophysiological recordings were performed in hippocampal slices 1d after the final injection. At this time, Delta(9)-THC was undetectable in hippocampus using liquid chromatography-mass spectrometry (LC-MS). Hippocampal LTP generated using high-frequency (HFS) or theta burst stimulation was not observed in brain slices from the 7-d Delta(9)-THC-treated animals. Delta(9)-THC also blocked HFS-LTP after 3 d, but not 1 d of treatment. The complete blockade of LTP persisted for 3 d after the last Delta(9)-THC injection, and full reversal of the LTP deficit was not observed up to 14 d following Delta(9)-THC withdrawal. The cannabinoid antagonist AM251 (2 mg/kg), administered before each Delta(9)-THC injection prevented the blockade of LTP, and 7-d treatment with AM251 alone significantly increased the level of LTP. Chronic Delta(9)-THC also produced tolerance to the inhibition of synaptic GABA, but not glutamate release by the agonist WIN55,212-2. These data define consequences of repeated Delta(9)-THC exposure for synaptic plasticity in the hippocampus that may help explain memory impairments in humans following chronic marijuana use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202425      PMCID: PMC1828281          DOI: 10.1101/lm.439007

Source DB:  PubMed          Journal:  Learn Mem        ISSN: 1072-0502            Impact factor:   2.460


  76 in total

1.  Neurocognitive consequences of marihuana--a comparison with pre-drug performance.

Authors:  P A Fried; B Watkinson; R Gray
Journal:  Neurotoxicol Teratol       Date:  2004-12-09       Impact factor: 3.763

2.  Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus.

Authors:  Alexander F Hoffman; Alice M Macgill; Dennison Smith; Murat Oz; Carl R Lupica
Journal:  Eur J Neurosci       Date:  2005-11       Impact factor: 3.386

Review 3.  Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions.

Authors:  Thomas Lundqvist
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

4.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

5.  Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.

Authors:  S A Varvel; D T Bridgen; Q Tao; B F Thomas; B R Martin; A H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2005-04-14       Impact factor: 4.030

6.  Endocannabinoids restrict hippocampal long-term potentiation via CB1.

Authors:  Kristen A Slanina; Marisa Roberto; Paul Schweitzer
Journal:  Neuropharmacology       Date:  2005-10       Impact factor: 5.250

7.  The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze.

Authors:  Reinaldo Naoto Takahashi; Fabrício Alano Pamplona; Marcelo Soares Fernandes
Journal:  Neurosci Lett       Date:  2005-02-16       Impact factor: 3.046

Review 8.  Rimonabant--a selective CB1 antagonist.

Authors:  Steven Thomas Boyd; Brad Allen Fremming
Journal:  Ann Pharmacother       Date:  2005-03-08       Impact factor: 3.154

9.  The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum.

Authors:  Yoshinobu Kawamura; Masahiro Fukaya; Takashi Maejima; Takayuki Yoshida; Eriko Miura; Masahiko Watanabe; Takako Ohno-Shosaku; Masanobu Kano
Journal:  J Neurosci       Date:  2006-03-15       Impact factor: 6.167

10.  The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus.

Authors:  K A Takahashi; P E Castillo
Journal:  Neuroscience       Date:  2006-03-09       Impact factor: 3.590

View more
  51 in total

1.  Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Authors:  Stephen A Varvel; Laura E Wise; Aron H Lichtman
Journal:  Drug Dev Res       Date:  2009-12-01       Impact factor: 4.360

2.  Altered parahippocampal functioning in cannabis users is related to the frequency of use.

Authors:  Benjamin Becker; Daniel Wagner; Euphrosyne Gouzoulis-Mayfrank; Elmar Spuentrup; Jörg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2010-03-19       Impact factor: 4.530

Review 3.  Molecular model of cannabis sensitivity in developing neuronal circuits.

Authors:  Erik Keimpema; Ken Mackie; Tibor Harkany
Journal:  Trends Pharmacol Sci       Date:  2011-07-13       Impact factor: 14.819

4.  Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission.

Authors:  Jimok Kim; Yong Li
Journal:  J Physiol       Date:  2015-01-05       Impact factor: 5.182

5.  Neuromolecular Mechanisms of Cannabis Action.

Authors:  Yousra Adel; Stephen P H Alexander
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

7.  Recruitment of hippocampal neurons to encode behavioral events in the rat: alterations in cognitive demand and cannabinoid exposure.

Authors:  Anushka V Goonawardena; Lianne Robinson; Gernot Riedel; Robert E Hampson
Journal:  Hippocampus       Date:  2010-09       Impact factor: 3.899

8.  Altered Corticolimbic Control of the Nucleus Accumbens by Long-term Δ9-Tetrahydrocannabinol Exposure.

Authors:  Eun-Kyung Hwang; Carl R Lupica
Journal:  Biol Psychiatry       Date:  2019-08-06       Impact factor: 13.382

9.  γ-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers.

Authors:  Andrew P Prescot; Perry F Renshaw; Deborah A Yurgelun-Todd
Journal:  Drug Alcohol Depend       Date:  2013-03-21       Impact factor: 4.492

10.  Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol.

Authors:  Laura E Wise; Andrew J Thorpe; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.